Bisphosphonate use in patients with lung cancer and bone metastases: Recommendations of a European expert panel

Filippo De Marinis, Wilfried Eberhardt, Peter G. Harper, Bartomeu Massuti Sureda, Kristiaan Nackaerts, Jens Benn Soerensen, Kostas Syrigos, Jean Trédaniel

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

INTRODUCTION: Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases in a variety of solid tumors, including lung cancer. The purpose of this article is to review the current evidence for the use of BPs in lung cancer and to provide specific European recommendations to support the clinical practice of using BPs to treat patients with lung cancer with bone metastases. METHODS: An expert panel of European clinical oncologists and lung cancer specialists convened for two face-to-face meetings designed to review available evidence on the efficacy of BPs in lung cancer and to develop recommendations based on published literature and clinical practice experiences. RESULTS: The panel recommends screening patients with lung cancer for bone metastases at the initial staging of disease to assess symptomatic bone metastases and screen for asymptomatic bone metastases and to allow accurate monitoring of bone disease progression and initiate bone-specific therapy. Bone assessment should be based on positron emission tomography (if available) or bone scan. BPs should be added to the treatment of patients with lung cancer (with non-small cell lung cancer or small cell lung cancer) who develop bone metastases. In such patients, BPs must be considered part of metastatic lung cancer treatment to prevent and delay the occurrence of further bone metastases and skeletal-related events and to relieve pain where present. BP treatment should continue for as long as it is practically feasible in the absence of any significant adverse effects.

Original languageEnglish
Pages (from-to)1280-1288
Number of pages9
JournalJournal of Thoracic Oncology
Volume4
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Bone Neoplasms
Diphosphonates
Lung Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Diseases
Small Cell Lung Carcinoma
Therapeutics
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Disease Progression
Pain
Incidence

Keywords

  • Bisphosphonates
  • Bone metastases
  • Lung cancer
  • Recommendations.
  • Skeletal- related events

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Bisphosphonate use in patients with lung cancer and bone metastases : Recommendations of a European expert panel. / De Marinis, Filippo; Eberhardt, Wilfried; Harper, Peter G.; Sureda, Bartomeu Massuti; Nackaerts, Kristiaan; Soerensen, Jens Benn; Syrigos, Kostas; Trédaniel, Jean.

In: Journal of Thoracic Oncology, Vol. 4, No. 10, 10.2009, p. 1280-1288.

Research output: Contribution to journalArticle

De Marinis, F, Eberhardt, W, Harper, PG, Sureda, BM, Nackaerts, K, Soerensen, JB, Syrigos, K & Trédaniel, J 2009, 'Bisphosphonate use in patients with lung cancer and bone metastases: Recommendations of a European expert panel', Journal of Thoracic Oncology, vol. 4, no. 10, pp. 1280-1288. https://doi.org/10.1097/JTO.0b013e3181b68e5a
De Marinis, Filippo ; Eberhardt, Wilfried ; Harper, Peter G. ; Sureda, Bartomeu Massuti ; Nackaerts, Kristiaan ; Soerensen, Jens Benn ; Syrigos, Kostas ; Trédaniel, Jean. / Bisphosphonate use in patients with lung cancer and bone metastases : Recommendations of a European expert panel. In: Journal of Thoracic Oncology. 2009 ; Vol. 4, No. 10. pp. 1280-1288.
@article{5b60d5c1b3d4498cbae71754b904dbbd,
title = "Bisphosphonate use in patients with lung cancer and bone metastases: Recommendations of a European expert panel",
abstract = "INTRODUCTION: Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases in a variety of solid tumors, including lung cancer. The purpose of this article is to review the current evidence for the use of BPs in lung cancer and to provide specific European recommendations to support the clinical practice of using BPs to treat patients with lung cancer with bone metastases. METHODS: An expert panel of European clinical oncologists and lung cancer specialists convened for two face-to-face meetings designed to review available evidence on the efficacy of BPs in lung cancer and to develop recommendations based on published literature and clinical practice experiences. RESULTS: The panel recommends screening patients with lung cancer for bone metastases at the initial staging of disease to assess symptomatic bone metastases and screen for asymptomatic bone metastases and to allow accurate monitoring of bone disease progression and initiate bone-specific therapy. Bone assessment should be based on positron emission tomography (if available) or bone scan. BPs should be added to the treatment of patients with lung cancer (with non-small cell lung cancer or small cell lung cancer) who develop bone metastases. In such patients, BPs must be considered part of metastatic lung cancer treatment to prevent and delay the occurrence of further bone metastases and skeletal-related events and to relieve pain where present. BP treatment should continue for as long as it is practically feasible in the absence of any significant adverse effects.",
keywords = "Bisphosphonates, Bone metastases, Lung cancer, Recommendations., Skeletal- related events",
author = "{De Marinis}, Filippo and Wilfried Eberhardt and Harper, {Peter G.} and Sureda, {Bartomeu Massuti} and Kristiaan Nackaerts and Soerensen, {Jens Benn} and Kostas Syrigos and Jean Tr{\'e}daniel",
year = "2009",
month = "10",
doi = "10.1097/JTO.0b013e3181b68e5a",
language = "English",
volume = "4",
pages = "1280--1288",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Bisphosphonate use in patients with lung cancer and bone metastases

T2 - Recommendations of a European expert panel

AU - De Marinis, Filippo

AU - Eberhardt, Wilfried

AU - Harper, Peter G.

AU - Sureda, Bartomeu Massuti

AU - Nackaerts, Kristiaan

AU - Soerensen, Jens Benn

AU - Syrigos, Kostas

AU - Trédaniel, Jean

PY - 2009/10

Y1 - 2009/10

N2 - INTRODUCTION: Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases in a variety of solid tumors, including lung cancer. The purpose of this article is to review the current evidence for the use of BPs in lung cancer and to provide specific European recommendations to support the clinical practice of using BPs to treat patients with lung cancer with bone metastases. METHODS: An expert panel of European clinical oncologists and lung cancer specialists convened for two face-to-face meetings designed to review available evidence on the efficacy of BPs in lung cancer and to develop recommendations based on published literature and clinical practice experiences. RESULTS: The panel recommends screening patients with lung cancer for bone metastases at the initial staging of disease to assess symptomatic bone metastases and screen for asymptomatic bone metastases and to allow accurate monitoring of bone disease progression and initiate bone-specific therapy. Bone assessment should be based on positron emission tomography (if available) or bone scan. BPs should be added to the treatment of patients with lung cancer (with non-small cell lung cancer or small cell lung cancer) who develop bone metastases. In such patients, BPs must be considered part of metastatic lung cancer treatment to prevent and delay the occurrence of further bone metastases and skeletal-related events and to relieve pain where present. BP treatment should continue for as long as it is practically feasible in the absence of any significant adverse effects.

AB - INTRODUCTION: Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases in a variety of solid tumors, including lung cancer. The purpose of this article is to review the current evidence for the use of BPs in lung cancer and to provide specific European recommendations to support the clinical practice of using BPs to treat patients with lung cancer with bone metastases. METHODS: An expert panel of European clinical oncologists and lung cancer specialists convened for two face-to-face meetings designed to review available evidence on the efficacy of BPs in lung cancer and to develop recommendations based on published literature and clinical practice experiences. RESULTS: The panel recommends screening patients with lung cancer for bone metastases at the initial staging of disease to assess symptomatic bone metastases and screen for asymptomatic bone metastases and to allow accurate monitoring of bone disease progression and initiate bone-specific therapy. Bone assessment should be based on positron emission tomography (if available) or bone scan. BPs should be added to the treatment of patients with lung cancer (with non-small cell lung cancer or small cell lung cancer) who develop bone metastases. In such patients, BPs must be considered part of metastatic lung cancer treatment to prevent and delay the occurrence of further bone metastases and skeletal-related events and to relieve pain where present. BP treatment should continue for as long as it is practically feasible in the absence of any significant adverse effects.

KW - Bisphosphonates

KW - Bone metastases

KW - Lung cancer

KW - Recommendations.

KW - Skeletal- related events

UR - http://www.scopus.com/inward/record.url?scp=70349685313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349685313&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181b68e5a

DO - 10.1097/JTO.0b013e3181b68e5a

M3 - Article

C2 - 19701109

AN - SCOPUS:70349685313

VL - 4

SP - 1280

EP - 1288

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 10

ER -